INDIANAPOLIS, Ind. - Eli Lilly and Company, a major pharmaceutical company, announced on Monday that its weight-loss drug, ...

Direct-to-consumer health startup Ro has partnered with Eli Lilly to provide more affordable ... loss drug Zepbound, streamlining access through a seamless platform. The initiative integrates ...

Now the shortages of Novo Nordisk's Wegovy and Eli Lilly & Co.'s Zepbound are over ... such a standard doesn't exist. Access to affordable compounded obesity medicines has been life-changing ...

Under Lilly’s savings-card program for commercially insured people who lack coverage for Zepbound, a one-month prescription for Zepbound pens now costs a minimum of $650, up from $550 previously.

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion (58.2 billlion Danish kroner). Access and affordability have limited wider use of the drugs.

CVS Health announced plans to drop Eli Lilly's Zepbound from its preferred coverage ... CVS said Caremark will offer Wegovy at "a more affordable price." As a pharmacy benefit manager, Caremark ...

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide (brand name Wegovy) in a 72-week clinical trial. The randomized, controlled trial — called ...

A new study published in the New England Journal of Medicine comparing Eli Lilly’s Zepbound to Novo Nordisk’s Wegovy — both approved to treat obesity — found that Zepbound is more ...

Zepbound generated $4.9 billion in global sales last year. Wegovy brought in nearly $8.8 billion. Access and affordability have limited wider use of the drugs. Tirzepatide and semaglutide were ...